GoldenGolden
Ligandal

Ligandal

Nanomedicine company developing vaccines and therapies with cell-specific targeting.

All edits

Edits on 11 May, 2021
Golden AI"Funding autocalculation"
Golden AI edited on 11 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding type
Series A round
Edits on 28 Mar, 2021
Golden AI"Found on funding round"
Golden AI edited on 28 Mar, 2021
Edits made to:
Infobox (+4 properties)
Infobox
Investors
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
May 15, 2019
Edits on 10 Aug, 2020
Aleksander Holm
Aleksander Holm edited on 10 Aug, 2020
Edits made to:
Infobox (--2 properties)
Infobox
Business model
Commerce
Edits on 30 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
4,580,000
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Edits on 27 Jul, 2020
Lax Mariappan
Lax Mariappan edited on 27 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2013
Edits on 20 Apr, 2020
Charlie Hilton
Charlie Hilton edited on 20 Apr, 2020
Edits made to:
Description (+1/-1 characters)
Topic thumbnail

Ligandal

Nanomedicine company developing vaccines and therapies with cell-specific targeting .

Edits on 16 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 16 Apr, 2020
Edits made to:
Further reading (+1/-1 rows) (+5 cells) (+210 characters)
Further reading

Title
Author
Link
Type
Date

Ligandal Proposes 'Antidote' to COVID-19 Using Robot-like Peptide Scaffolds

Gail Dutton

Web

April 16, 2020

Edits on 15 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 15 Apr, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 8 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Full address
650 5th Street, Suite 311, San Francisco, CA 94107
Edits on 18 Mar, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 18 Mar, 2020
Edits made to:
Article (+12/-12 characters)
Article

Ligandal is a nanomedicine company using gene editing tools such as CRISPR and cell-specific targeting molecules or ligands. CEO and Founder Andre WatsonAndre Watson is an inventor on 43 issued or pending patents for nucleic acid and protein delivery with cell-specific targeting molecules. Watson aims to enable biological systems to be programmed at will to treat disease and extend lifespan.

Meredith Hanel
Meredith Hanel edited on 18 Mar, 2020
Edits made to:
Article
Further reading (+2 rows) (+5 cells) (+147 characters)
Article

Ligandal’s approach for rapid vaccine prototyping and scalable vaccine development is being applied to developing a vaccine for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The company designed a fully synthetic scaffold that mimics the epitopes which are bound by T-cell receptors and antibodies. The scaffold can be custom-tailored to new mutant forms of the virus. For therapeutic agents, the scaffold can serve as a targeting ligand that mimics viral entry into target diseased cells and tissues. The “mini viral” scaffolds can be synthesized in hours and rapidly scaled to 100 kg or more, and the company says that their process of peptide synthesis is much less expensive than for mRNA-based vaccines or therapies.

...

Ligandal is working with government resources and private groups to use their technology for SARS-CoV-2 vaccine and therapeutic development. Ligandal’s SARS-CoV-2 vaccine design includes immune-epitopic regions for T cell receptor MHC-1 and MHC-2 loading, antibody binding and ACE2 receptor binding regions in vaccine scaffolds of less than 70 amino acids. The scaffolds can serve as competitive inhibitors for ACE2 binding by the virus and are also designed to trigger the immune system to learn to fight the SAR-CoV-2 virus.

...

Ligandal has results which show they are able to predict binding pockets, using computer modeling and deep learning approaches, that are consistent with Cryo-EM and other high-resolution structural data. The company believes their peptide scaffold approach can be quickly tailored to new applications or mutated viral epitopic regions within days or weeks. Therapeutic agents such as silencing RNAs, CRISPR molecules and small molecule agents can be targeting to virally-infected cells using with their approach.

Further reading

Title
Author
Link
Type
Date

Gene Editing Startups Fabricate Industrial-Grade CRISPR Tools

Gail Dutton

Journal

June 2019

Meredith Hanel
Meredith Hanel edited on 17 Mar, 2020
Edits made to:
Description (+84/-20 characters)
Article (+2172 characters)
Categories (+2/-1 topics)
Topic thumbnail

Ligandal

Gene therapy company

Nanomedicine company developing vaccines and therapies with cell-specific targeting

Article

Ligandal is a nanomedicine company using gene editing tools such as CRISPR and cell-specific targeting molecules or ligands. CEO and Founder Andre Watson is an inventor on 43 issued or pending patents for nucleic acid and protein delivery with cell-specific targeting molecules. Watson aims to enable biological systems to be programmed at will to treat disease and extend lifespan.

Ligandal’s approach for rapid vaccine prototyping and scalable vaccine development is being applied to developing a vaccine for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The company designed a fully synthetic scaffold that mimics the epitopes which are bound by T-cell receptors and antibodies. The scaffold can be custom-tailored to new mutant forms of the virus. For therapeutic agents, the scaffold can serve as a targeting ligand that mimics viral entry into target diseased cells and tissues. The “mini viral” scaffolds can be synthesized in hours and rapidly scaled to 100 kg or more, and the company says that their process of peptide synthesis is much less expensive than for mRNA-based vaccines or therapies.

Ligandal is working with government resources and private groups to use their technology for SARS-CoV-2 vaccine and therapeutic development. Ligandal’s SARS-CoV-2 vaccine design includes immune-epitopic regions for T cell receptor MHC-1 and MHC-2 loading, antibody binding and ACE2 receptor binding regions in vaccine scaffolds of less than 70 amino acids. The scaffolds can serve as competitive inhibitors for ACE2 binding by the virus and are also designed to trigger the immune system to learn to fight the SAR-CoV-2 virus.

Ligandal has results which show they are able to predict binding pockets, using computer modeling and deep learning approaches, that are consistent with Cryo-EM and other high-resolution structural data. The company believes their peptide scaffold approach can be quickly tailored to new applications or mutated viral epitopic regions within days or weeks. Therapeutic agents such as silencing RNAs, CRISPR molecules and small molecule agents can be targeting to virally-infected cells using with their approach.

Categories
Edits on 21 Feb, 2020
Golden AI"Adding location topic from lookup San Francisco, CA"
Golden AI edited on 21 Feb, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.